Literature DB >> 33377626

Novel mutations in hyper-IgM syndrome type 2 and X-linked agammaglobulinemia detected in three patients with primary immunodeficiency disease.

Xihui Chen1, Fangfang Liu2, Lijuan Yuan1,3, Meng Zhang1, Kun Chen4, Yuanming Wu1.   

Abstract

BACKGROUND: Ambiguous or atypical phenotypes can make a definite diagnosis of primary immunodeficiency diseases based on biochemical indices alone challenging. Further, mortality in early life because of infections in patients with these conditions supports the use of genetic tests to facilitate rapid and accurate diagnoses.
METHODS: Genetic and clinical analyses of three unrelated Chinese children with clinical manifestations of recurrent infections, who were considered to have primary immunodeficiency diseases, were conducted. Patient clinical features and serum immunological indices were recorded. Next-generation sequencing was used to screen for suspected pathogenic variants. Family co-segregation and in silico analysis were conducted to evaluate the pathogenicity of identified variants, following the American College of Medical Genetics and Genomics guidance.
RESULTS: All three patients were found to have predominant antibody defects. Sequencing analysis revealed that one had two compound heterozygous variants, c.255C>A and c.295C>T, in the autosomal gene, activation-induced cytidine deaminase (AICDA). The other two patients were each hemizygous for the variants c.1185G>A and c.82C>T in the Bruton's tyrosine kinase (BTK) gene on the X chromosome. In silico analysis revealed that identified substituted amino acids were highly conserved and predicted to cause structural and functional damage to the proteins.
CONCLUSION: Four pathogenic variants in AICDA and BTK were confirmed to cause different forms of hyper-IgM syndrome type 2 (HIGM2) and X-linked agammaglobulinemia (XLA); two were novel mutations that have never been reported previously. This is the first report of HIGM2 caused by AICDA deficiency in a patient from the Chinese mainland.
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Entities:  

Keywords:  X-linked agammaglobulinemia; hyper-IgM syndrome type 2; molecular diagnosis; next-generation sequencing; primary immunodeficiency diseases

Year:  2020        PMID: 33377626      PMCID: PMC7963428          DOI: 10.1002/mgg3.1552

Source DB:  PubMed          Journal:  Mol Genet Genomic Med        ISSN: 2324-9269            Impact factor:   2.183


  29 in total

Review 1.  Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control of B-cell development from immature to mature B cells.

Authors:  F Melchers; E ten Boekel; T Seidl; X C Kong; T Yamagami; K Onishi; T Shimizu; A G Rolink; J Andersson
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

2.  Treatment of Chronic Enterovirus Encephalitis With Fluoxetine in a Patient With X-Linked Agammaglobulinemia.

Authors:  Jacqueline Gofshteyn; Ana María Cárdenas; David Bearden
Journal:  Pediatr Neurol       Date:  2016-06-25       Impact factor: 3.372

Review 3.  Activation-induced cytidine deaminase: structure-function relationship as based on the study of mutants.

Authors:  Anne Durandy; Sophie Peron; Nadine Taubenheim; Alain Fischer
Journal:  Hum Mutat       Date:  2006-12       Impact factor: 4.878

4.  Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene.

Authors:  T Muto; M Muramatsu; M Taniwaki; K Kinoshita; T Honjo
Journal:  Genomics       Date:  2000-08-15       Impact factor: 5.736

Review 5.  Use of Genetic Testing for Primary Immunodeficiency Patients.

Authors:  Jennifer R Heimall; David Hagin; Joud Hajjar; Sarah E Henrickson; Hillary S Hernandez-Trujillo; Yuval Tan; Lisa Kobrynski; Kenneth Paris; Troy R Torgerson; James W Verbsky; Richard L Wasserman; Elena W Y Hsieh; Jack J Blessing; Janet S Chou; Monica G Lawrence; Rebecca A Marsh; Sergio D Rosenzweig; Jordan S Orange; Roshini S Abraham
Journal:  J Clin Immunol       Date:  2018-04-19       Impact factor: 8.317

Review 6.  Clinical Phenotypes of Hyper-IgM Syndromes.

Authors:  M Teresa de la Morena
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

7.  Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome.

Authors:  Y Minegishi; A Lavoie; C Cunningham-Rundles; P M Bédard; J Hébert; L Côté; K Dan; D Sedlak; R H Buckley; A Fischer; A Durandy; M E Conley
Journal:  Clin Immunol       Date:  2000-12       Impact factor: 3.969

8.  BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients.

Authors:  Marcelo A Teocchi; Vanessa Domingues Ramalho; Beatriz M Abramczuk; Lília D'Souza-Li; Maria Marluce Santos Vilela
Journal:  Immun Inflamm Dis       Date:  2015-06-04

Review 9.  Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.

Authors:  Beatriz E Marciano; Steven M Holland
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

10.  Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: Report from Shanghai, China (2000-2015).

Authors:  Xia-Fang Chen; Wei-Fan Wang; Yi-Dan Zhang; Wei Zhao; Jing Wu; Tong-Xin Chen
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more
  3 in total

1.  A novel complex genomic rearrangement affecting the KCNJ2 regulatory region causes a variant of Cooks syndrome.

Authors:  Luigia Cinque; Lucia Micale; Elena Manara; Andrea Esposito; Orazio Palumbo; Andrea Maria Chiariello; Simona Bianco; Giulia Guerri; Matteo Bertelli; Maria Grazia Giuffrida; Laura Bernardini; Angelantonio Notarangelo; Mario Nicodemi; Marco Castori
Journal:  Hum Genet       Date:  2021-11-25       Impact factor: 4.132

2.  Neuroepigenetic Changes in DNA Methylation Affecting Diabetes-Induced Cognitive Impairment.

Authors:  Valencia Fernandes; Kumari Preeti; Anika Sood; Kala P Nair; Sabiya Khan; B S Shankaranarayana Rao; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2022-09-22       Impact factor: 4.231

Review 3.  Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2.

Authors:  M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan
Journal:  Hum Genet       Date:  2021-07-30       Impact factor: 4.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.